High materiality7/10
Kymera Therapeutics price target raised to $140 from $120 at Mizuho
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Mizuho raises Kymera Therapeutics’ target to 140; current price is 114.12, indicating meaningful upside.
- Target above current price; notable upside potential.
Key facts
- 01
Target: $58
- 02
Posted price: $47.21
- 03
Analyst firm: Morgan Stanley
- 04
Analyst: Vincent Andrews
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.